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PTargeted Iron Oxide Particles for In Vivo Magnetic
Resonance Detection of Atherosclerotic Lesions With
Antibodies Directed to Oxidation-Specific Epitopes
Karen C. Briley-Saebo, PHD,* Young Seok Cho, MD,† Peter X. Shaw, PHD,
Sung Kee Ryu, MD, PHD,‡ Venkatesh Mani, PHD,* Stephen Dickson, MS,* Ehsan Izadmehr,*
Simone Green, BS, Zahi A. Fayad, PHD,*§ Sotirios Tsimikas, MD
New York, New York; Seoul, South Korea; and La Jolla, California
Objectives The aim of this study was to determine whether iron oxide particles targeted to oxidation-specific epitopes
image atherosclerotic lesions.
Background Oxidized low-density lipoprotein plays a major role in atherosclerotic plaque progression and destabilization.
Prior studies indicate that gadolinium micelles labeled with oxidation-specific antibodies allow for in vivo detec-
tion of vulnerable plaques with magnetic resonance imaging (MRI). However, issues related to biotransforma-
tion/retention of gadolinium might limit clinical translation. Iron oxides are recognized as safe and effective
contrast agents for MRI. Because the efficacy of passively targeted iron particles remains variable, it was hypoth-
esized that iron particles targeted to oxidation-specific epitopes might increase the utility of this platform.
Methods Lipid-coated ultra-small superparamagnetic iron particles (LUSPIOs) (20 nm) and superparamagnetic iron par-
ticles (40 nm) were conjugated with antibodies targeted to either malondialdehyde-lysine or oxidized phospho-
lipid epitopes. All formulations were characterized, and their in vivo efficacy evaluated in apolipoprotein E defi-
cient mice 24 h after bolus administration of a 3.9-mg Fe/kg dose with MRI. In vivo imaging data were
correlated with the presence of oxidation-specific epitopes with immunohistochemistry.
Results MRI of atherosclerotic lesions, as manifested by signal loss, was observed after administration of targeted
LUSPIOs. Immunohistochemistry confirmed the presence of malondialdehyde-epitopes and iron particles. Lim-
ited signal attenuation was observed for untargeted LUSPIOs. Additionally, no significant arterial wall uptake
was observed for targeted or untargeted lipid-coated superparamagnetic iron oxide particles, due to their limited
ability to penetrate the vessel wall.
Conclusions This study demonstrates that LUSPIOs targeted to oxidation-specific epitopes image atherosclerotic lesions and
suggests a clinically translatable platform for the detection of atherosclerotic plaque. (J Am Coll Cardiol 2011;
57:337–47) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.09.023l
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st is now well-established that plaque vulnerability is mainly
inked to plaque composition and not necessarily to the
egree of luminal narrowing (1). Diagnostic tools that can
ccurately characterize plaque composition, particularly
omponents that mediate the transition of stable plaques to
ulnerable/high-risk plaques, are needed to monitor disease
nd predict cardiovascular events (2). Oxidized low-density
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elevated levels of circulating oxi-
dized phospholipids on apoli-
poprotein B-100 particles predict
the presence and extent of an-
giographically defined coronary
artery disease; progression of ca-
rotid and femoral artery athero-
sclerosis; and death, myocardial
infarction, and stroke in uns-
elected populations from the
general community (5–8). There-
fore development of sensitive
molecular imaging probes that
target oxidation-specific epitopes
in the vessel wall might allow for
in vivo detection of rupture-
prone plaques.
Magnetic resonance imaging
(MRI) has emerged as a promis-
ing diagnostic modality, due to its
sub-millimeter spatial-resolution,
for both the direct assessment of
plaque burden and the evaluation
of plaque composition (9,10).
The magnetic resonance (MR)
efficacy of gadolinium (Gd) pe-
gylated (PEG) micelles targeted
to oxidation-specific epitopes in
imaging aortic atherosclerosis
in apolipoprotein E deficient
(apoE/) mice was recently re-
ported (11). Those studies also
indicated that targeted Gd mi-
elles accumulate in macrophages after binding OxLDL
xtracellularly and therefore might also be a sensitive imag-
ng technique to identify intraplaque macrophages in vivo.
Although the efficacy of this platform has been demon-
trated, the long circulation times (14 h) and high liver
ptake (approximately 20% of the injected dose) of such Gd
icelles might limit clinical translation, due to safety-
elated issues. Reported studies have indicated that intra-
ellular uptake of Gd chelates might result in de-metallation
nd subsequent cell apoptosis (12,13). Studies in mice using
d micelles have also shown significant transmetallation
ue to the prolonged circulation times exhibited by lipid-
ased nanoparticles relative to low molecular weight Gd
helates (14). Additionally, it has been hypothesized that
ransmetallation induces the nephrogenic systemic fibrosis
n renally impaired patients after injection of clinically
vailable low molecular weight Gd chelates (15).
The primary aim of the current study was to evaluate
he efficacy of biocompatible iron oxide particles targeted
o oxidation-specific epitopes in imaging atherosclerotic
esions. Dextran-coated ultrasmall iron oxide particles
Abbreviations
and Acronyms
apoE/  apolipoprotein
E deficient
Gd  gadolinium
GRASP  gradient echo
acquisition for
superparamagnetic
particles with positive
contrast
GRE  gradient echo
ICP-MS  inductively
coupled plasma mass
spectrometry
LDL  low-density
lipoprotein
LSPIO  lipid-coated
superparamagnetic iron
oxide particle
LUSPIO  lipid-coated
ultra-small
superparamagnetic iron
particle
MDA  malondialdehyde
MR  magnetic resonance
MRI  magnetic resonance
imaging
OxLDL  oxidized low-
density lipoprotein
PEG  pegylated
RES  reticuloendothelial
system
USPIO  ultrasmall iron
oxide particleUSPIOs) have been used to passively target intraplaqueacrophages (16–18). These USPIOs are desirable from a
afety point of view, because cells associated with the
eticuloendothelial system (RES) are able to safely eliminate
ron (19). However, this passive targeting strategy might be
uboptimal, because these materials require slow infusion
nd long time-intervals between administration and MRI
24 h) (17,20). Therefore, we hypothesized that lipid-
oated iron oxide particles targeted to oxidation-specific
pitopes might increase the clinical utility of the iron oxide
latform for MRI of vulnerable atherosclerotic plaque.
ethods
o assess the effect of core size on the magnetization (and
esultant MR signal) and hydrated particle size on the
bility to penetrate the arterial wall, 2 types of iron oxide
articles were evaluated: oxidation-specific, epitope-
argeted, lipid-coated, ultrasmall superparamagnetic iron
xide particles (LUSPIOs), and larger lipid-coated super-
aramagnetic iron oxide particles (LSPIOs). Although the
USPIOs are expected to exhibit better wall penetration,
SPIOs are expected to generate greater MR signal loss. It
s currently unclear whether it is more advantageous to have
greater number of less-effective particles within the wall or
fewer number of more-effective particles within the
rterial wall.
A full description of the Methods is given in the Online
ppendix. A brief overview is given in the following text.
ynthesis of oxidation-specific, epitope-targeted iron
xide particles. Two murine (malondialdehyde [MDA]2
nd E06) and 1 fully human single-chain (IK17) Fv
ntibody fragment targeted to oxidation-specific epitopes
ere covalently attached (0.35 mg/mg Fe) to the sur-
ace of monocrystalline and monodisperse LUSPIO and
SPIO particle surface via S-acetylthioglycolic acid
-hydroxysuccinimide ester modification (Fig. 1). The
ipid-coated LUSPIOs were prepared by first synthesizing
he iron core, as previously reported for Clariscan
NC100150 Injection, Amersham). The LSPIOs were pre-
ared according to previously reported techniques (see
Figure 1 Diagram
Schematic diagram of the lipid-coated iron oxide particles formed.
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January 18, 2011:337–47 In Vivo Imaging of Oxidation-Specific Epitopesnline Appendix for details). These iron oxide particles
ontain PEG side chains rather than dextran.
haracterization of iron oxide particles. All samples were
oncentrated to 1 mg Fe/ml; sterile filtered; and character-
zed with respect to iron content, hydrated particle size,
article structure, longitudinal (r1) and transverse (r2) re-
axation properties, and stability with respect to storage.
n vitro macrophage uptake of iron oxide particles. Pre-
ious in vitro studies have shown that oxidation-specific,
pitope-targeted Gd micelles exhibit increased macrophage
ptake, particularly when pre-incubated with the MDA–
ow-density lipoprotein (LDL) (21). Because iron oxide
articles are known to also passively target macrophages, in
itro cell studies were performed to determine the extent of
assive macrophage uptake. Macrophages were pre-exposed
o MDA-LDL for 24 h. Then the following materials were
dded to the macrophages: 1) 1 mmol/l Fe of untargeted
USPIO (n  2); 2) 1 mmol/l Fe of MDA2-labeled
USPIO (n  2); 3) 1 mmol/l Fe of untargeted LSPIO
n  2); and 4) 1 mmol/l Fe of MDA2-labeled LSPIO
n  2). Feridex (Berlex, Inc., Wayne, New Jersey)
1 mmol/l Fe) and saline (0.15 ml) were used as controls.
he rationale for using Feridex as a positive control is
elated to published studies that show strong macrophage
ptake of dextran-coated iron oxide particles, such as
eridex, fractionated Feridex, and Combidex (Advanced
agnetics). Iron content within macrophages was deter-
ined with inductively coupled plasma mass spectrometry
ICP-MS). Laser scanning confocal microscopy and Perl’s
russian Blue staining (for determination of intracellular
ron deposition) were also performed using standard
ethods.
nimal models and pharmacokinetics and RES uptake.
ight- to ten-month-old apoE/ mice on a C57BL/6
ackground on a high-cholesterol diet (0.2% total cholesterol,
arlan Teklad, Madison, Wisconsin) ad libitum beginning at
weeks until 32 to 40 weeks of age were used for all studies.
ge-matched C57BL/6 wild-type (WT) mice on normal
how until 32 to 40 weeks of age were used as control subjects.
he blood half-lives and liver uptake were determined with
tandard relaxometry methods after animals were administered
.9 mg Fe/kg LSPIO or LSPIO via retro-orbital injection.
he percentage injected dose was determined on the basis of
he iron concentration/g wet organ weight.
RI. All MRIs were performed at 9.4-T with a 89-mm
ore system operating at a proton frequency of 400 MHz
Bruker Instruments, Billerica, Massachusetts) before and
4 h after the administration of a 3.9-mg Fe/kg dose. To
btain in vivo R2* maps, multiple gradient echo (GRE)
equences with the following pulse sequence parameters
ere applied: repetition time 29.1 ms, echo time 5.1 to
0 ms (n  5), flip angle  30°, number of signal averages 
, in-plane resolution  0.098 mm2, and 100% z-rephasing
radient. Twenty slices were acquired from the level of the
enal arteries to the iliac bifurcation. The R2*-maps were
enerated for the matched pre- and post-images on a cixel-by-pixel basis using a custom Matlab program
R2007b, Mathworks, Natick, Massachusetts). The signal
ntensity associated with each pixel was normalized to the
D of adjacent noise (placed above the spine of the mouse)
efore linear fitting of the signal-to-noise ratio versus echo
ime. The R2* values were then obtained with regions of
nterest drawn on the arterial wall on slices (n  5)
xhibiting either R2* modulation after contrast or arterial
all thickening, indicative of plaque deposition. The rela-
ive percentage change in the R2* values were determined
s: % change  ([R2*postR2*pre]/R2*post) · 100.
Immediately after GRE acquisition, a gradient echo
cquisition for superparamagnetic particles with positive
ontrast (GRASP) sequence was applied using 50% of the
-rephasing gradient. The GRASP sequence is extremely
seful when trying to determine whether MR signal loss is
ue to iron oxide deposition or other endogenous artifacts
motion, partial voluming, and peri-vascular effects) that
ight also promote signal loss. The GRASP sequence
annot be used alone, however, because this sequence does
ot provide adequate anatomic information. In similarity to
RE sequences, GRASP signal might be observed in
ymphatic tissue that might also sequester the iron oxide
articles. However, this sequence is extremely useful to
ifferentiate between iron oxide deposition and artifacts that
re often present when imaging the arterial wall. Previously
ublished studies at lower magnetic fields (1.5- to 3.0-T)
ave shown that the GRASP sequence is most effective
hen the rephrasing gradient is reduced from 100% to 25%
o 30% (22,23). However, at 9.4-T, preliminary studies
ndicate that a reduction in the z-rephasing gradient from
00% to 50% allows for adequate susceptibility matching
nd signal gain. As a result, for the GRASP sequence all
arameters were held constant (relative to the GRE se-
uence) except for the z-rephasing gradient that was re-
uced to 50%. Because equivalent imaging geometry was
sed for both GRE and GRASP, the imaging results
btained from these sequences were directly matched and
ompared.
ompetitive inhibition studies. The specificity of the
DA2-labeled LUSPIOs for MDA-lysine epitopes within
he vessel wall of apoE/ mice was evaluated with in vivo
ompetitive inhibition. Age-matched apoE/ mice (n 
) were coadministered 3 mg of free MDA2 antibody and
.9 mg Fe/kg MDA2-labeled LUSPIOs via tail vein
njection. The MR enhancement (as R2*) of arterial wall
as determined and compared with the enhancement
bserved after the administration of MDA2-labeled
USPIOs only (n  9).
mmunohistochemistry. Immunohistochemistry in se-
ected atherosclerotic plaques for macrophages, MDA-
ysine epitopes, and iron oxide deposition (Perl’s Prussian
lue) was performed.
tatistical analysis. One-way analysis of variance with
onferroni post-hoc multiple comparison tests was used to
ompare the R2* values obtained as a function of time
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ne-way analysis of variance was used to compare the mean
alues obtained 24 h after injection. For all statistical
nalysis, p  0.05 was considered significant.
esults
haracterization of iron oxide particles. The physical and
hemical properties of the iron oxide formulations are
ummarized in Table 1. The LSPIOs exhibited significantly
reater hydrated particle diameters, iron core sizes (Fig. 2),
nd dipolar r2 values relative to the LUSPIO. The negative
ransmission electron microscopy images show the iron core
dark) surrounded by lipids (light), thereby indicating effec-
ive lipid coating of the iron cores. Additionally, the
ransmission electron microscopy images show large poly-
isperse LSPIO iron cores that might comprise either
ultiple small cores or one large core. Although the presence
hysical and Chemical Properties of LUSPIOs and LSPIOsTable 1 Physical and Chemical Properties of LUSPIOs and LSP
Formulation
Size
(nm)
r1
(s1 mmol/l1)
r2
(s1 mmol/l1)
Untargeted LUSPIO 10 3 14 1 35 2
Untargeted LSPIO 35 5 12 1 103 4
MDA2 LUSPIO 14 3 13 1 37 2
MDA2 LSPIO 38 4 11 1 117 5
IK17 LUSPIO 12 2 14 1 35 2
IK17 LSPIO 36 4 10 1 106 5
E06 LUSPIO 16 4 12 1 38 2
E06 LSPIO 39 5 11 1 119 6
ll sizes are based upon the weighted number averages. The relaxivities shown were obtained in b
btained in apolipoprotein E deficient (apoE/) or wild type (WT) mice after injection of a 3.9-m
IK17  human antibody; LSPIO  lipid-coated superparamagnetic iron oxide particle; LUSPIO 
Figure 2 TEM
Transmission electron microscopy (TEM) and negative TEM of untargeted lipid-
coated ultrasmall superparamagnetic iron oxide particle (LUSPIO) and lipid-
coated superparamagnetic iron oxide particle (LSPIO) formations. The red
asterisks indicate the iron core. The red arrow points to the lipid layer associ-
ated with the particles.f single, large iron cores (crystal sizes10 nm) might lead to
erromagnetism at physiological temperatures, we were unable
o obtain magnetic hysteresis loops (to confirm remanence) due
o instrument limitations.
The r2/r1 ratio observed for the LUSPIO was within the
eported range of monocrystalline superparamagnetic iron
xide particles (24). Compared with the NC100150 Injec-
ion, however, the relatively high LUSPIO r2/r1 values were
ikely due to variations in the iron core synthesis that
esulted in the formation of a polydisperse LUSPIO mate-
ial. This was confirmed by the LUSPIO r1 nuclear mag-
etic relaxation dispersion profile (Fig. 3) that does not
xhibit a low field dispersion characteristic of monocrystalline
nd monodisperse USPIOs (25). At clinical imaging field
trengths (60 MHz) no significant difference was observed
etween the r1 values obtained for LUSPIOs and LSPIOs.
he dipolar r2 values of the LSPIO were significantly greater
han the values obtained for the LUSPIO at all field strengths
ested. This result was expected, because the iron core and
ydrated particles sizes were larger for this material.
The batch-to-batch variability of the untargeted LUSPIO
nd LSPIO formulations, as represented by the relative SD,
lood Half-Life ApoE/
(h)
Blood Half-Life WT
(h)
%ID in Liver
(24 h p.i.)
1.52 1.41 25
1.02 1.01 35
9.01 1.55 31
7.28 1.12 37
9.12 31
7.30 34
9.32 30
7.42 35
t 60 MHz and 40°C. All blood half-lives and percentage injected (p.i.) dose (%ID) in the liver were
dose.
oated ultra-small superparamagnetic iron particle; MDA2 and E06  murine antibodies.
Figure 3 Nuclear Magnetic Relaxation Dispersion Profiles
The longitudinal (r1) and transverse (r2) nuclear magnetic relaxation
dispersion profiles of untargeted LSPIOs and LUSPIOs. Abbreviations as in Figure 2.IOs
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January 18, 2011:337–47 In Vivo Imaging of Oxidation-Specific Epitopesas 10% with respect to both the hydrated particle size and
2/r1 values. Both formulations exhibited limited (5%) vari-
tion in size and/or r2/r1 values after 30-day storage at 4°C.
hese data strongly suggest that the iron formulations might
e stored for up to 1 month without significant change in the
ydrated particle size and relaxation properties.
Figure 4 summarizes the in vitro uptake of the untargeted
nd MDA2-labeled LUSPIOs and LSPIOs. The results
uggest that PEG coating of the iron particles significantly
imits J7774A.1 macrophage uptake. The ICP-MS con-
rmed only nominal uptake of untargeted LUSPIOs and
SPIOs (below detection limits). However, conjugation of
he MDA2 antibody to the surface of the particles resulted
n significant increases in the LSPIO (0.4 pg Fe/cell) and
USPIO (0.31 pg Fe/cell) uptake, as confirmed by histol-
gy. Incubation with Feridex resulted in strong unspecific
ptake (1.9 pg Fe/cell), as anticipated. Although the uptake
f the MDA2-labeled LUSPIO/LSPIOs might seem lim-
ted, relative to Feridex, it should be emphasized that only 1
n every 16 LUSPIO/LSPIO contains a targeting MDA2
ntibody. This ratio was chosen to ensure that no more than
antibody was associated with an individual particle (to
revent aggregation) and due to limited availability of some
f the antibodies used. As a result, only 6% of the LUSPIO/
SPIO dose is expected to be mediated into the cell. If
Figure 4 Macrophage Uptake of Iron Oxide Particles
In vitro J774A.1 macrophage uptake of untargeted lipid-coated iron particles (nega
trol). All cells were incubated with 1 mmol/l Fe for 24 h. Both Perl’s staining for ir
performed. In addition, iron oxide particle uptake was determined with inductively
Figure 2.very LUSPIO/LSPIO particle was MDA2-labeled (1:1
atio), a theoretical uptake of 5 to 6 pg Fe/cell is expected
assuming linear uptake).
The targeted formulations exhibited prolonged circula-
ion times relative to the untargeted material in apoE/
ice. In WT mice, no significant variations in the blood
alf-lives were observed between the untargeted and
xidation-specific targeted formulations. This is consistent
ith data reported for oxidation-specific epitope targeted
d micelles and suggests that interactions between the
argeted particles and circulating OxLDL might prolong
irculation times (11). Although the LUSPIOs exhibited
ignificantly longer circulation times relative to the LSPIOs
p  0.01), no significant variation in liver uptake was
bserved between the targeted and untargeted formulations
4 h after injection (Table 1). When compared with
istorical NC100105 Injection data, the untargeted LUSPIOs
xhibited significantly reduced liver uptake (80% injected
ose vs. 25% injected dose) (Table 1), thereby suggesting
hat modification of the LUSPIO coating inhibited uptake
y the RES (26).
n Vivo MRI. There were no clinical signs indicative of
oxicity during or after iron oxide administration. Rep-
esentative in vivo MR images obtained before and 24 h
fter injection of the LUSPIO formulations are shown in
ntrol), targeted lipid-coated iron particles, and Feridex (Berlex, Inc.) (positive con-
e uptake and confocal microscopy (rhodamine-labeled LUSPIOs/LSPIOs) were
d plasma mass spectrometry and reported in pg Fe/cell. Abbreviations as intive co
on oxid
couple
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RASP sequence was useful for differentiation between
ymphatic drain (dark on GRE images and dark on GRASP
mages) and iron deposition within the arterial wall (dark on
RE images and bright on GRASP). Although nominal
ignal loss was observed after administration of the untar-
eted LUSPIOs, significant loss (p  0.003) was observed
4 h after administration of the oxidation-specific epitope
Figure 5 LUSPIO MRI of ApoE/ Mice
(A) Representative in vivo LUSPIO magnetic resonance images obtained before (P
deficient (apoE/) mice. The yellow arrows indicate the position of the lumen as
obtained with an echo time of 7 ms. Corresponding white marker gradient echo ac
also shown. The apoE/ mice were administered free excess MDA2 antibody at
Matched histology sections show iron deposition (blue) within foam cells associat
the arterial wall after administration of the LUSPIO formulations are also shown (B
ing untargeted LUSPIOs and antibody-labeled LUSPIOs. MRI  magnetic resonanceargeted LUSPIOs in apoE/ mice, as confirmed by Iistology. Perl’s staining also suggests that most iron dep-
sition occurs in lesions rich in both MDA epitopes and
acrophages/foam cells. Both MDA2 and IK17 targeted
USPIOs exhibited similar MR efficacy (p  0.61), as
eflected in the percentage change in the R2* values asso-
iated with the arterial wall (Fig. 5). The MR efficacy was,
owever, significantly higher for E06 LUSPIOs (p 0.019)
hat target oxidized phospholipids, relative to MDA2 and
d 24 h after (POST) administration of a 3.9-mg Fe/kg dose in apolipoprotein E
ed with the abdominal aorta. All gradient echo (GRE) images shown were
on for superparamagnetic particles with positive contrast (GRASP) images are
e of MDA2-labeled LUSPIO injection, for the competitive inhibition results.
h the arterial wall. Relative percentage change in the R2* values associated with
error bars reflect the SD associated with mean value obtained for mice receiv-
ing; other abbreviations as in Figures 2 and 4.RE) an
sociat
quisiti
the tim
ed wit
). The
imagK17 that target MDA or MDA-like epitopes. The in vivo
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January 18, 2011:337–47 In Vivo Imaging of Oxidation-Specific Epitopesompetitive inhibition studies showed a 74.9% (p 0.0002)
eduction in R2* for mice administered free MDA2 at the
ime of MDA2-labeled LUSPIO micelle injection (Fig. 5).
Limited signal attenuation was observed after adminis-
ration of untargeted and oxidation-specific, epitope-
argeted LSPIOs (Fig. 6) in mice with significant athero-
clerotic lesions. These findings strongly suggest that the
SPIOs are too large to allow for optimal diffusion into
he arterial vessel wall. Additionally, the faster blood clear-
nce of the LSPIO (Table 1) formulation might limit the
mount of time in which these particles might have to
iffuse into the wall.
Additionally, no significant (p  0.22) arterial wall uptake
as observed in WT mice after injection of the various iron
xide formulations tested. Perl’s staining confirmed nominal
ron oxide deposition associated with oxidation-specific
pitopes in age-matched WT mice. These findings are con-
istent with previously reported data that show no significant
p  0.5) uptake of oxidation-specific, targeted nanoparticles
n the arterial wall of WT mice (11).
orrelation with the presence of oxidation-specific epitopes
nd macrophages with immunohistochemistry. Immuno-
istochemistry performed on a random subgroup of
poE/ mice administered the MDA2-labeled LUSPIO
howed strong correlation between iron oxide (Perl’s stain-
ng) and MDA-lysine epitope (MDA3 staining) deposition
Figure 6 Ultrasmall Iron Oxide Particle MRI of ApoE/ Mice
Representative in vivo LSPIO magnetic resonance images obtained before and 24
and E06 formulations are shown in A. The yellow arrows indicate the position of t
with an echo time of 7 ms. Corresponding white marker GRASP images are also s
associated with the arterial wall. Relative percentage change in the R2* values as
shown (B). The error bars reflect the SD associated with mean value obtained for
4, and 5.Fig. 7). Limited LUSPIO and MDA-lysine was observed
n age-matched WT mice. Additionally, confocal micros-
opy confirmed the uptake of the oxidation-specific, tar-
eted LUSPIOs (rhodamine-labeled) within atherosclerotic
esions and specifically within intraplaque macrophages/
oam cells (anti-CD68–labeled) 24 h after injection (Fig. 7).
hodamine-labeled targeted LUSPIOS were not observed
n the extracellular matrix. These results are consistent with
he findings reported for MDA2-Gd micelles (11). Addi-
ionally, strong colocalization between MDA epitopes and
erl’s Prussian Blue staining was observed, thereby confirm-
ng the presence of the targeted LUSPIOs in macrophages/
oam cells enriched in oxidation-specific epitopes.
iscussion
he results of the current study demonstrate that it is
easible to noninvasively image atherosclerotic lesions en-
iched in oxidation-specific epitopes with biocompatible,
argeted, iron oxide MR molecular imaging probes. Reflect-
ng the robustness of this approach, three different antibod-
es recognizing unique oxidation-specific epitopes demon-
trated strong imaging characteristics. Furthermore,
argeted LUSPIOs were more efficacious in imaging ath-
rosclerotic plaques, relative to larger targeted LSPIOs that
xhibited restricted accumulation within the arterial wall.
r administration of a 3.9-mg Fe/kg dose in apoE/ mice. Only the untargeted
en associated with the abdominal aorta. The GRE images shown were obtained
Matched histology sections show limited iron deposition (blue) within foam cells
ed with the arterial wall after administration of the LUSPIO formulations are also
eceiving untargeted and antibody-labeled LSPIOs. Abbreviations as in Figures 2,h afte
he lum
hown.
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pitopes might provide significant advantages when com-
ared with current passive iron-oxide targeting approaches.
or example, a wealth of animal and clinical data has
Figure 7 Immunohistochemistry
Immunohistochemistry (A) and confocal microscopy (B) of MDA2-labeled LUSP
for MDA-lysine (MDA3 staining), macrophages (Mac3), and iron oxide (Perl’s) d
between the cell nuclei (blue), macrophages (green), and MDA2-labeled LUSPIOsemonstrated that oxidation-specific epitopes closely reflect the presence of atherosclerosis, plaque vulnerability, and
linical events (2,8,27,28). Whereas passively targeted
extran-coated iron oxide particles are taken up by a variety
f macrophages located within the arterial wall and adven-
the arterial wall of apoE/ and wild-type mice. The arterial wall was stained
ion. Confocal microscopy with a multi-channel laser so that colocalization
ould be performed. Abbreviations as in Figures 2, 4, and 5.IOs in
eposit
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January 18, 2011:337–47 In Vivo Imaging of Oxidation-Specific Epitopesicelles) do not seem to be selectively taken up by macro-
hages unless they also contain an oxidation-specific anti-
ody. In this way, the epitope-targeted PEG nanoparticles
eem to selectively accumulate primarily within lipid-rich
acrophage foam cells, perhaps due to binding extracellular
xLDL at these sites or to OxLDL bound on macrophage
cavenger receptors, which then mediates enhanced uptake.
s a result, molecular imaging probes that actively target
xidation-specific epitopes might eventually allow for in
ivo evaluation of plaque vulnerability. Furthermore, pre-
linical studies have shown that, during atherosclerosis
egression and plaque stabilization, oxidation-specific
pitopes are removed before any significant geometric
laque regression (3,29), suggesting that monitoring of
isease activity in response to therapeutic interventions
ight be feasible. In the current study, the specific targeting
f the targeted LUSPIOs was demonstrated by the follow-
ng: 1) untargeted control LUSPIOs exhibited limited in
itro macrophage uptake and nominal in vivo lesion en-
ancement; 2) oxidation-specific targeted LUSPIOs exhib-
ted in vitro macrophage uptake and strong in vivo arterial
all enhancement in apoE/ mice; 3) no in vivo
xidation-specific targeted LUSPIO uptake was observed in
he arterial wall of age-matched WT mice; and 4) co-
reatment of animals with free MDA2 and MDA2-labeled
USPIOS resulted in reduced MR signal enhancement due
o blocking of available antibody binding sites. Additionally,
n contrast to passively targeted iron oxide particles, targeted
articles may be administered as a bolus at clinically relevant
ron dosages (5 mg Fe/kg) and MRI may be performed
ithin 24 h.
The results of the current study also suggest that in vivo
fficacy is modulated by the ability of the particles to
enetrate the arterial wall and not by the in vitro MR
fficacy (as determined by the dipolar r2 values). It was
vident that, even though the 35-nm LSPIOs exhibited
-fold greater r2 values (3 times more effective at inducing
R signal loss relative to the LUSPIOs), the size of these
articles restricted uptake into the arterial wall. For iron
articles to be taken up by intraplaque macrophages, they
ust either penetrate the endothelium or diffuse into the
laque via the neovasculature. Because apoE/ mice ex-
ibit limited plaque neo-vascularization, intraplaque mac-
ophage uptake is primarily dependent upon arterial wall
iffusion. Unlike other flexible lipid nanoparticles such as
iposomes and lipoproteins, iron oxide particles are rigid
pheres that are unable to modify their shape to migrate
hrough smaller pore sizes (30). Convective flow studies
redict that the aortic endothelial tight junction associated
ith plaque is approximately 25 nm (31). Because the
argeted LUSPIOs were smaller than these gap junctions
20 nm), they exhibited greater arterial wall diffusion
nd subsequent intraplaque macrophage uptake relative
o equivalent LSPIOS. However, it is anticipated that the
ptimal targeted iron oxide particle would maintain high t2 values (large iron core size) and have a total hydrated
ize 25 nm.
The increased blood half-life of the targeted particles was
ikely beneficial from an imaging efficacy point of view,
ecause this might allow for greater time for accumulation
f the particles within the arterial wall. That the smaller
argeted LUSPIOs exhibited significantly longer circulation
imes relative to the LSPIOs is consistent with other studies
hat show large iron particles are generally cleared much
aster than equivalent smaller particles (32,33). All iron
ormulations, however, exhibited lower plasma half-lives
elative to oxidation-specific, epitope-targeted Gd micelles
9 h vs. 14 h) (11). The reduced circulation times are likely
elated to variations in the surface charge (6 mV for the
d micelles, and 2 mV for the iron particles) and/or total
umber of particles injected. Although variations in blood
learance were observed, no significant difference in liver
ptake was observed for any of the formulations tested at
4 h after injection. The limited liver uptake (40%) is
uggestive of high uptake into tissue associated with the
ononuclear phagocytic system (spleen, bone, lymph, and
o forth) (33,34). However, these tissues were not analyzed
or iron oxide content, due to the amount of tissue required
o perform iron assays with relaxometry. Europium-
nriched iron oxide formulations will be used in the future
o obtain accurate biodistribution data with neutron activa-
ion techniques.
For the LUSPIOs, no significant difference in the MR
fficacy, pharmacokinetics, or liver uptake was observed
etween MDA2 and IK17 particles. Previous studies have
hown that both radiolabeled MDA2 and IK17 localize to
ipid-rich, oxidation-rich atherosclerotic lesions in mice
3,29,35). Additionally, studies using oxidation-specific,
pitope-targeted Gd micelles show limited variation in the
R signal obtained 24 to 72 h after injection of the MDA2
r IK17 formations. In the current study, significantly
reater MR enhancement (as R2*) was observed after
dministration of the E06-labeled LUSPIOs. Although the
easons for this are not clear, it might be possible that the
esions studies exhibited more enriched oxidized phospho-
ipid epitopes relative to MDA epitopes. The actual mech-
nism by which the oxidation-specific targeted particles
ccumulate within the arterial wall and are sequestered by
ntraplaque macrophages is still under investigation. Fur-
hermore, although the R2* values obtained within the
rterial wall correlate qualitatively with the presence of
xidation-specific epitopes and macrophages, additional
tudies are needed to quantitatively determine whether the
trength of the signal correlates with evidence of plaque
ulnerability. Studies are currently underway to correlate
he in vivo R2* signal with histology in LDL receptor/
ice during dietary intervention. Furthermore, both
DA2 and E06 are murine antibodies, and although they
emonstrate the principal of targeting oxidation-specific
pitopes very well, they cannot be used in clinical applica-
ions without humanizing them. However, IK17 is a fully
h
c
h
o
c
t
C
T
b
o
t
c
v
o
A
T
U
m
a
S
n
R
V
9
s
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
346 Briley-Saebo et al. JACC Vol. 57, No. 3, 2011
In Vivo Imaging of Oxidation-Specific Epitopes January 18, 2011:337–47uman, stable single chain fragment and thus a viable
andidate for further pre-clinical evaluation for imaging
uman atherosclerotic lesions. The relative potential safety
f iron oxide particles compared with Gd-containing mi-
elles suggests a shorter pathway to clinical translation of
his platform.
onclusions
he present study demonstrates a sensitive, specific, and
iocompatible method for the noninvasive imaging of
xidation-specific epitopes within the arterial wall. Due to
he limited toxicity issues associated with iron oxide parti-
les, if validated in humans, this approach might provide
aluable tools for the noninvasive detection and monitoring
f atherosclerosis.
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